Poor graft function (PGF) is a life-threatening complication that occurs after transplantation
and has a poor prognosis. With the rapid development of haploidentical hematopoietic stem …

Abstract Purpose of Review Philadelphia-negative myeloproliferative neoplasms (MPNs)
include polycythemia vera (PV), essential thrombocythemia (ET), prefibrotic (pre-), and overt …

Secondary poor graft function (sPGF) increases the risk of life-threatening complications
after hematopoietic stem cell transplantation (HSCT). The incidence, clinical outcomes, and …

Moving from indication to transplantation is a critical process in myelofibrosis. Most of
guidelines specifically focus on either myelofibrosis disease or transplant procedure, and …

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by a highly
heterogeneous clinical course, which can be complicated by severe constitutional …

Allogeneic hematopoietic cell transplantation (alloHCT) is indicated for patients with
intermediate-risk or high-risk myelofibrosis (MF) and remains the sole potential cure …

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation,
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …

In this review, we will outline dimensions in which outcome of patients with myelofibrosis
undergoing curative treatment can be optimized: patient selection, transplant procedure, and …

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm with a very heterogenous
clinical course. Median survival of patients with overt MF is close to 6 years, but with great …

Philadelphia-negative myeloproliferative neoplasms (MPNs) regroup hematological
malignancies arising from the clonal expansion of a hematopoietic stem cell (HSC) and lead …